Table 2.
PROMIS clinical validation study groups, demographics, and clinical characteristics
| Back pain (n = 218) |
Cancer (n = 310) |
Chronic heart failure (n = 60) |
Chronic obstructive pulmonary disease, exacerbation (n = 46) |
Chronic obstructive pulmonary disease, stable (n = 79) |
Major depressive disorder (n = 196) |
Rheumatoid arthritis (n = 521) |
|
|---|---|---|---|---|---|---|---|
| Female gender | 121 (56%) | 189 (61%) | 12 (20%) | 18 (39%) | 35 (44%) | 145 (74%) | 422 (81%) |
| Age category, y | |||||||
| 18–29 | 17 (8%) | 3 (1%) | 2 (4%) | 0 | 0 | 47 (24%) | 2 (>1%) |
| 30–39 | 17 (8%) | 8 (3%) | 5 (10%) | 0 | 0 | 25 (13%) | 18 (3%) |
| 40–49 | 48 (22%) | 59 (19%) | 10 (20%) | 4 (9%) | 1 (1%) | 30 (15%) | 39 (7%) |
| 50–59 | 55 (25%) | 90 (29%) | 16 (33%) | 23 (50%) | 24 (30%) | 13 (7%) | 114 (22%) |
| 60–69 | 43 (20%) | 69 (23%) | 14 (29%) | 10 (22%) | 27 (34%) | 56 (29%) | 164 (31%) |
| 70+ | 38 (17%) | 77 (25%) | 2 (4%) | 9 (20%) | 27 (34%) | 24 (12%) | 184 (35%) |
| Missing | 0 | 4 | 11 | 0 | 0 | 1 | 0 |
| Median age group | 55–59 | 50–54 | 50–54 | 55–59 | 60–64 | 45–49 | 65–69 |
| Race, ethnicity | |||||||
| White, non-Hispanic | 183 (84%) | 243 (81%) | 50 (86%) | 33 (73%) | 56 (72%) | 145 (78%) | 454 (88%) |
| Black, non-Hispanic | 7 (3%) | 33 (11%) | 7 (12%) | 12 (27%) | 19 (24%) | 26 (14%) | 19 (4%) |
| Other, non-Hispanic | 15 (7%) | 10 (3%) | 1 (2%) | 0 | 2 (3%) | 4 (2%) | 15 (3%) |
| Hispanic, any race | 10 (5%) | 14 (5%) | 0 | 0 | 1 (1%) | 10 (5%) | 27 (5%) |
| Missing | 3 | 10 | 2 | 1 | 1 | 11 | 6 |
| ECOG PSR | |||||||
| 0 | 102 (33%) | ||||||
| 1 | 135 (44%) | ||||||
| 2 | 47 (15%) | ||||||
| 3 | 21 (7%) | ||||||
| Missing | 5 | ||||||
| NYHA classification | |||||||
| II (slight limitation) | 1 (2%) | ||||||
| III (marked limitation) | 28 (50%) | ||||||
| IV (severe limitation) | 27 (48%) | ||||||
| Missing | 4 | ||||||
| COPD state | |||||||
| Stable | 0 | 79 (100%) | |||||
| Exacerbation resolving | 8 (17%) | 0 | |||||
| Exacerbation current | 38 (83%) | 0 | |||||
| MRC breathlessness rating | |||||||
| 1 (not breathless) | 2 (4%) | 14 (18%) | |||||
| 2 | 15 (33%) | 30 (38%) | |||||
| 3 | 9 (20%) | 20 (25%) | |||||
| 4 | 14 (30%) | 15 (19%) | |||||
| 5 (too breathless to leave the house) | 6 (13%) | 0 | |||||
| Worst back pain, past 7 days | |||||||
| 0–3 | 8 (4%) | 91 (47%) | |||||
| 4–6 | 25 (12%) | 37 (19%) | |||||
| 7 | 24 (11%) | 12 (6%) | |||||
| 8 | 49 (23%) | 21 (11%) | |||||
| 9 | 49 (23%) | 17 (9%) | |||||
| 10 | 60 (28%) | 17 (9%) | |||||
| Missing | 3 | 1 | |||||
| Worst leg pain, past 7 days | |||||||
| 0–3 | 45 (21%) | 116 (59%) | |||||
| 4–6 | 36 (17%) | 21 (11%) | |||||
| 7 | 20 (9%) | 13 (7%) | |||||
| 8 | 41 (19%) | 19 (10%) | |||||
| 9 | 34 (16%) | 10 (5%) | |||||
| 10 | 40 (19%) | 16 (8%) | |||||
| Missing | 2 | 1 | |||||
| CES-D score | |||||||
| <16 (not depressed) | 81 (38%) | 18 (9%) | |||||
| 16–21 | 60 (28%) | 36 (18%) | |||||
| 22–27 | 33 (15%) | 56 (29%) | |||||
| 28–34 | 20 (9%) | 50 (26%) | |||||
| 35+ | 19 (9%) | 35 (18%) | |||||
| Missing | 5 | 1 | |||||
| HAQ Disability Indexa | |||||||
| Mean (SD) | 0.90 (0.73) | ||||||
| Median (range) | 0.75 (0–3) | ||||||
| 0–1 | 295 (57%) | ||||||
| 1–2 | 181 (35%) | ||||||
| 2–3 | 45 (9%) |
Abbreviations: PROMIS, Patient Reported Outcome Measurement Information System; ECOG PSR, Eastern Cooperative Oncology Group Performance Status Rating; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; MRC, Medical Research Council; CES-D, Center for Epidemiological Studies Depression Scale; HAQ, Health Assessment Questionnaire; SD, standard deviation.
a
Scoring was not adjusted for aids and devices.